Purpose: To determine whether mitomycin-C can inhibit posterior capsule opa
cification (PCO) without causing ocular toxicity.
Setting: Yonsei Institute of Vision Research, Department of Ophthalmology,
Yonsei University College of Medicine, Seoul, Korea.
Methods: Mitomycin-C dissolved in sodium hyaluronate (0.2 cc of 0.2 mg/mL)
was injected into the empty capsular bag for 3 minutes after endocapsular p
hacoemulsification in rabbit eyes. Three months after surgery, the obstruct
ion rate of visible light caused by PCO was measured using an optical power
meter.
Results: The mean obstruction rate of visible light was 81.0% +/- 8.3% (SD)
in the control group in which sodium hyaluronate without mitomycin-C was u
sed, 30.5% +/- 10.1% in the group in which mitomycin-C was dissolved in sod
ium hyaluronate, and 71.9% +/- 6.8% in the group in which mitomycin-C was d
issolved in a balanced salt solution. Statistically significant differences
were found among all 3 groups.
Conclusion: Our results suggest that the application of mitomycin-C dissolv
ed in sodium hyaluronate effectively reduces PCO in rabbit eyes. J Cataract
Refract Surg 2000; 26:1537-1542 (C) 2000 ASCRS and ESCRS.